Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07202546 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
A Phase 2 study of HIV Infections, sponsored by ViiV Healthcare.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT07202546: Recruiting Phase 2 study of HIV Infections, sponsored by ViiV Healthcare.
NCT07202546 is a Phase 2 study of HIV Infections that is actively recruiting participants, run by ViiV Healthcare. The registered enrollment target is 150 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07202546, a Phase 2 study of HIV Infections, is actively recruiting participants, sponsored by ViiV Healthcare.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.
Conditions Studied
Interventions
- DRUG VH4524184
- DRUG Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets
- DRUG Dolutegravir / Lamivudine (DTG/3TC)
Study Locations (20)
Florida
- GSK Investigational Site - Ft. Pierce
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami Gardens
- GSK Investigational Site - Oakland Park
- GSK Investigational Site - Orlando
- GSK Investigational Site - Orlando
- GSK Investigational Site - West Palm Beach
California
- GSK Investigational Site - Bakersfield
- GSK Investigational Site - Palm Springs
- GSK Investigational Site - West Hollywood
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Macon
Missouri
- GSK Investigational Site - Columbia
- GSK Investigational Site - Kansas City
North Carolina
- GSK Investigational Site - Greensboro
- GSK Investigational Site - Wilmington
Texas
- GSK Investigational Site - Bellaire
- GSK Investigational Site - Longview
Nebraska
- GSK Investigational Site - Omaha
New Jersey
- GSK Investigational Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-02-11 |
| Est. Completion | 2028-09-22 |
| Phase | Phase 2 |
What NCT07202546 shows while recruiting
NCT07202546 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (66% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which VH4524184 is the first listed.
NCT07202546 names 20 study sites across 8 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07202546 about?
NCT07202546 is a clinical study titled "A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)". This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/...
What is the current status of trial NCT07202546?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2026-02-11. Estimated completion is 2028-09-22.
What conditions does trial NCT07202546 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT07202546?
The interventions under investigation include: VH4524184 (DRUG), Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets (DRUG), Dolutegravir / Lamivudine (DTG/3TC) (DRUG).
Who is sponsoring clinical trial NCT07202546?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07202546 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07202546's enrollment target sits among peer trials
150 212th of 542 higher than 328 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI